Dyadic Reports 2024 Year-End Financial Results and Business Updates
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 ...
American Association of Individual Investors5d
Which Is a Better Investment, Elanco Animal Health Incorporated or Harmony Biosciences Holdings, Inc. Stock?
Learn more about whether Elanco Animal Health Incorporated or Harmony Biosciences Holdings, Inc. is a better investment based ...
Yahoo Finance9d
A Practical Approach to Developing CMC Packaging for Veterinary Pharmaceutical Products in the EU Virtual Training Course
Dublin, March 17, 2025 (GLOBE NEWSWIRE) -- The "A Practical Approach to Developing the CMC Package for Veterinary Pharmaceutical Products Training Course" has been added to ResearchAndMarkets.com ...
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...
Benzinga.com7d
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Telomir Pharmaceuticals plans to submit an IND application by year-end to advance Telomir-1 into clinical trials. Volatility can create massive trading opportunities—if you know how to ...
The Herald SC7d
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
"These results not only confirm in-vitro observations in aggressive, androgen-independent human prostate cancer cells but also represent a game-changing discovery in animal models. We are seeing a ...
Benzinga.com7d
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Telomir Pharmaceuticals plans to submit an IND application by year-end to advance Telomir-1 into clinical trials. Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to ...